IP and Start-ups- A presentation by Dr. Kalyan C. Kankanala at IIMB
Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala
-
Upload
bananaip-counsels -
Category
Law
-
view
82 -
download
0
description
Transcript of Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala
![Page 1: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/1.jpg)
Biotechnology and IP By
Dr. Kalyan Kankanala
Blog: www.bananaip.com/sinapse-blog
![Page 2: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/2.jpg)
US Patent Law and Biotechnology
![Page 3: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/3.jpg)
Overview
• Article 1 Section 1 Clause 8
• Quid Pro Quo
• Incentives
• Title 35
• www.uspto.gov
• www.fedcir.gov
![Page 4: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/4.jpg)
Patentability requirements
• Patentable subject matter
• Utility
• Novelty
• Nonobviousness
• Specification
![Page 5: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/5.jpg)
INVENTIONS
Subject Matter
Usefulness
Novelty
Non-obviousness
Specification
PATENTS
Kalyan’s Patent Filter Model
![Page 6: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/6.jpg)
Patentable Subject Matter
• Section 101 - Process, machine, manufacture, composition of matter and Improvements
• Funk Bros. v. Kalo
• Diamond v. Chakrabarty
• Pioneer Hibebred v. J.E.M.
Arguments and Issues
![Page 7: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/7.jpg)
Funk Bros
• Rhizobium bacteria
• Innoculum of mutually inhibiting bacteria
• Is it a product of nature?
![Page 8: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/8.jpg)
Chakrabarty's case
• Psuedomonas bacteria
• Four different plasmids inserted.
• Is it a product of Nature?
![Page 9: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/9.jpg)
Utility
• Current
• Substantial
• Credible
• Brenner v. Manson
• Gene/protein sequences
![Page 10: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/10.jpg)
Novelty
• Section 102
• Known or used
• Patented or published
• Public use or On sale
• Abandoned
• Foreign Priority
• Patented in another country
![Page 11: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/11.jpg)
Novelty
• Derived
• Suppressed or Concealed
• Diligence
• Single prior art reference
• Isolated or purified- activity
• Hybritech v. Monoclonal
![Page 12: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/12.jpg)
Nonobviousness
• Scope of prior art
• Differences- invention and prior art
• Level of ordinary skill
• Secondary Indicia
• At the time of conception
• Obvious to try
![Page 13: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/13.jpg)
Hybritech v. Monoclonal
• immunometric assays using monoclonal antibodies
![Page 14: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/14.jpg)
Prior Art
• a. Kohler and Milstein's Nobel Prize-Winning Work for Producing Monoclonal antibodies in vitro;
• b. The Work of Drs. Oi and Herzenberg, in which they used monoclonal antibodies to "map" epitopes or determine the number and location of different antibody binding sites on a known quantity of IgE antigen by attaching to it an antibody bound to a carrier and exposing that antigen to other monoclonal antibodies;
• c. The Frankel Article that disclosed Monoclonal Antibodies Having Affinities of 109 liters/mole; and
• d. Articles "Predicting" Widespread Use of Monoclonal antibodies.
![Page 15: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/15.jpg)
In re Deuel:
• Isolated and purified DNA and cDNA sequences encoding heparin-binding growth factors ("HBGFs")
![Page 16: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/16.jpg)
Prior Art
• Bohlen's patent application disclosed a group of protein growth factors designated as heparin-binding brain mitogens ("HBBMs") useful in treating burns and promoting the formation, maintenance, and repair of tissue, particularly neural tissue. Bohlen determined the first 19 amino acids of the proteins' N-terminal sequences, which were found to be identical for human and bovine HBBMs. He provided no teachings concerning DNA or cDNA coding for HBBMs in his application.
![Page 17: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/17.jpg)
Prior Art
• Maniatis described a method of isolating DNAs or cDNAs by screening a DNA or cDNA library with a gene probe. The reference outlined a general technique for cloning a gene but did not describe how to isolate a particular DNA or cDNA molecule.
![Page 18: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/18.jpg)
Recent Developments
• KSR Vs. Teleflex
• In re Kubin
![Page 19: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/19.jpg)
Specification
• Written Description
• Enablement
• Best Mode
• Claims
• Object: Notice and Dissemination
![Page 20: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/20.jpg)
Example
• A stent coated with taxol for "treating or preventing recurrent stenosis.
• Prior ArtStents Existing
• Taxol known for Tumor treatment by angiogenesis
• Article - Re-stenosis dangers and need for a treatment - suggests various options
![Page 21: Biotechnology and IP - A Presentation by Dr. Kalyan Kankanala](https://reader033.fdocuments.net/reader033/viewer/2022060107/554c3201b4c9050d1b8b526b/html5/thumbnails/21.jpg)
Have a nice day
For more information:
www.bananaip.com
www.bananaip.com/sinapse-blog
Email: [email protected]